Genscript Biotech Corporation (GNNSF) Stock

About Genscript Biotech Corporation

Genscript Biotech Corporation, an investment holding firm, operates on a global scale as a leading provider of life science research products and services, serving North America, Europe, China, Japan, other Asia Pacific regions, and beyond. The company is structured into four distinct business units. Its Life Science Services and Products division delivers essential research support, encompassing gene synthesis, molecular cloning, oligonucleotide and peptide synthesis, protein engineering, antibody development, and the creation of molecular diagnostic tools and genome editing materials. These offerings cater to diverse fields such as fundamental biological research, pharmaceutical development, drug discovery, disease diagnostics, vaccine production, agriculture, environmental research, and the food sector. The Biologics Development Services segment provides comprehensive support for drug development, assisting pharmaceutical, biotechnology, government, and academic organizations. This includes antibody drug discovery, preclinical and clinical development of antibody therapeutics, and the preclinical and clinical advancement of plasmids and viruses for gene and cell therapies. Within its Industrial Synthetic Biology Products segment, the company specializes in engineering non-pathogenic microbial strains and manufacturing industrial enzymes. These are applied across various industries, including food processing, animal feed, pharmaceuticals, and chemicals. Finally, the Cell Therapy division is dedicated to the discovery and development of chimeric antigen receptor T-cell (CAR T-cell) therapies specifically for treating both liquid and solid tumors. Established in 2002, Genscript Biotech Corporation is headquartered in Nanjing, People's Republic of China.

Genscript Biotech Corporation is headquartered in CN.

Genscript Biotech Corporation (GNNSF) stock trades at $3.08 with a market capitalization of $6.73B. The stock is valued at a price-to-earnings (P/E) ratio of -12.23, price-to-book of 1.70, price-to-sales of 7.01. Over the past 52 weeks the stock has ranged between $1.30 and $3.08, and currently trades at its 52-week high.

On profitability, Genscript Biotech Corporation generates a return on equity (ROE) of -12.72%, return on capital employed of 6.18%, an operating margin of 26.60%, a net profit margin of -55.53%.

Official website: www.genscript.com